Overactive Bladder Drug Market

List of Tables
Table 1. Overactive Bladder Drug CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Overactive Bladder Drug Market Trends
Table 3. Overactive Bladder Drug Market Drivers
Table 4. Overactive Bladder Drug Market Challenges
Table 5. Overactive Bladder Drug Market Restraints
Table 6. Global Overactive Bladder Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Overactive Bladder Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Overactive Bladder Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Overactive Bladder Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Overactive Bladder Drug Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Overactive Bladder Drug Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Overactive Bladder Drug Revenue Share by Manufacturer, 2017-2022
Table 13. Global Overactive Bladder Drug Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Overactive Bladder Drug Sales Share by Manufacturer, 2017-2022
Table 15. Global Overactive Bladder Drug Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global Overactive Bladder Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Overactive Bladder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2021)
Table 18. Top Players of Overactive Bladder Drug in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Overactive Bladder Drug Product Type
Table 20. Date of International Manufacturers Enter into Overactive Bladder Drug Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Overactive Bladder Drug Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Overactive Bladder Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Overactive Bladder Drug Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Overactive Bladder Drug Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Overactive Bladder Drug Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Overactive Bladder Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Overactive Bladder Drug Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Overactive Bladder Drug Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Overactive Bladder Drug Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Overactive Bladder Drug Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Overactive Bladder Drug Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Overactive Bladder Drug Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Overactive Bladder Drug Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Overactive Bladder Drug Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Overactive Bladder Drug Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Overactive Bladder Drug Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Overactive Bladder Drug Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Overactive Bladder Drug Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Overactive Bladder Drug Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Overactive Bladder Drug Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Astellas Pharma, Inc. (Japan) Corporation Information
Table 43. Astellas Pharma, Inc. (Japan) Description and Business Overview
Table 44. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product
Table 46. Astellas Pharma, Inc. (Japan) Recent Development
Table 47. Pfizer, Inc. (US) Corporation Information
Table 48. Pfizer, Inc. (US) Description and Business Overview
Table 49. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. Pfizer, Inc. (US) Product
Table 51. Pfizer, Inc. (US) Recent Development
Table 52. Teva Pharmaceutical Industries Limited (Israel) Corporation Information
Table 53. Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview
Table 54. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Teva Pharmaceutical Industries Limited (Israel) Product
Table 56. Teva Pharmaceutical Industries Limited (Israel) Recent Development
Table 57. Allergan, Plc (Ireland) Corporation Information
Table 58. Allergan, Plc (Ireland) Description and Business Overview
Table 59. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Allergan, Plc (Ireland) Product
Table 61. Allergan, Plc (Ireland) Recent Development
Table 62. Medtronic plc (Ireland) Corporation Information
Table 63. Medtronic plc (Ireland) Description and Business Overview
Table 64. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Medtronic plc (Ireland) Product
Table 66. Medtronic plc (Ireland) Recent Development
Table 67. Mylan N.V. (US) Corporation Information
Table 68. Mylan N.V. (US) Description and Business Overview
Table 69. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Mylan N.V. (US) Product
Table 71. Mylan N.V. (US) Recent Development
Table 72. Endo International plc (Ireland) Corporation Information
Table 73. Endo International plc (Ireland) Description and Business Overview
Table 74. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. Endo International plc (Ireland) Product
Table 76. Endo International plc (Ireland) Recent Development
Table 77. Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
Table 78. Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview
Table 79. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 80. Hisamitsu Pharmaceutical Co., Inc. (Japan) Product
Table 81. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
Table 82. Sanofi (France) Corporation Information
Table 83. Sanofi (France) Description and Business Overview
Table 84. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 85. Sanofi (France) Product
Table 86. Sanofi (France) Recent Development
Table 87. Apotex, Inc. (Canada) Corporation Information
Table 88. Apotex, Inc. (Canada) Description and Business Overview
Table 89. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 90. Apotex, Inc. (Canada) Product
Table 91. Apotex, Inc. (Canada) Recent Development
Table 92. Cogentix Medical, Inc. (US) Corporation Information
Table 93. Cogentix Medical, Inc. (US) Description and Business Overview
Table 94. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 95. Cogentix Medical, Inc. (US) Product
Table 96. Cogentix Medical, Inc. (US) Recent Development
Table 97. Aurobindo Pharma Limited (India) Corporation Information
Table 98. Aurobindo Pharma Limited (India) Description and Business Overview
Table 99. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 100. Aurobindo Pharma Limited (India) Product
Table 101. Aurobindo Pharma Limited (India) Recent Development
Table 102. Key Raw Materials Lists
Table 103. Raw Materials Key Suppliers Lists
Table 104. Overactive Bladder Drug Customers List
Table 105. Overactive Bladder Drug Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Overactive Bladder Drug Product Picture
Figure 2. Global Overactive Bladder Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Overactive Bladder Drug Market Size 2017-2028 (US$ Million)
Figure 4. Global Overactive Bladder Drug Sales 2017-2028 (K Units)
Figure 5. United States Overactive Bladder Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Overactive Bladder Drug Market Size 2017-2028 (US$ Million)
Figure 7. United States Overactive Bladder Drug Sales 2017-2028 (K Units)
Figure 8. United States Overactive Bladder Drug Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Overactive Bladder Drug Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Overactive Bladder Drug Report Years Considered
Figure 11. Product Picture of Anticholinergics
Figure 12. Product Picture of Solifenacin
Figure 13. Product Picture of Oxybutynin
Figure 14. Product Picture of Darifenacin
Figure 15. Product Picture of Fesoterodine
Figure 16. Product Picture of Tolterodine
Figure 17. Product Picture of Trospium
Figure 18. Product Picture of Others
Figure 19. Global Overactive Bladder Drug Market Share by Type in 2022 & 2028
Figure 20. Global Overactive Bladder Drug Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. Global Overactive Bladder Drug Sales Market Share in Value by Type (2017-2028)
Figure 22. Global Overactive Bladder Drug Sales by Type (2017-2028) & (K Units)
Figure 23. Global Overactive Bladder Drug Sales Market Share in Volume by Type (2017-2028)
Figure 24. Global Overactive Bladder Drug Price by Type (2017-2028) & (USD/Unit)
Figure 25. United States Overactive Bladder Drug Market Share by Type in 2022 & 2028
Figure 26. United States Overactive Bladder Drug Sales in Value by Type (2017-2028) & (US$ Million)
Figure 27. United States Overactive Bladder Drug Sales Market Share in Value by Type (2017-2028)
Figure 28. United States Overactive Bladder Drug Sales by Type (2017-2028) & (K Units)
Figure 29. United States Overactive Bladder Drug Sales Market Share in Volume by Type (2017-2028)
Figure 30. United States Overactive Bladder Drug Price by Type (2017-2028) & (USD/Unit)
Figure 31. Product Picture of Idiopathic Bladder Overactivity
Figure 32. Product Picture of Neurogenic Bladder Overactivity
Figure 33. Global Overactive Bladder Drug Market Share by Application in 2022 & 2028
Figure 34. Global Overactive Bladder Drug Sales in Value by Application (2017-2028) & (US$ Million)
Figure 35. Global Overactive Bladder Drug Sales Market Share in Value by Application (2017-2028)
Figure 36. Global Overactive Bladder Drug Sales by Application (2017-2028) & (K Units)
Figure 37. Global Overactive Bladder Drug Sales Market Share in Volume by Application (2017-2028)
Figure 38. Global Overactive Bladder Drug Price by Application (2017-2028) & (USD/Unit)
Figure 39. United States Overactive Bladder Drug Market Share by Application in 2022 & 2028
Figure 40. United States Overactive Bladder Drug Sales in Value by Application (2017-2028) & (US$ Million)
Figure 41. United States Overactive Bladder Drug Sales Market Share in Value by Application (2017-2028)
Figure 42. United States Overactive Bladder Drug Sales by Application (2017-2028) & (K Units)
Figure 43. United States Overactive Bladder Drug Sales Market Share in Volume by Application (2017-2028)
Figure 44. United States Overactive Bladder Drug Price by Application (2017-2028) & (USD/Unit)
Figure 45. North America Overactive Bladder Drug Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 46. North America Overactive Bladder Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 47. U.S. Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. Canada Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Europe Overactive Bladder Drug Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 50. Europe Overactive Bladder Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 51. Germany Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. France Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. U.K. Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Italy Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. Russia Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Asia-Pacific Overactive Bladder Drug Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 57. Asia-Pacific Overactive Bladder Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 58. China Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Japan Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. South Korea Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. India Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Australia Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Taiwan Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Indonesia Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Thailand Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Malaysia Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Philippines Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Latin America Overactive Bladder Drug Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 69. Latin America Overactive Bladder Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 70. Mexico Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Brazil Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Argentina Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Middle East & Africa Overactive Bladder Drug Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 74. Middle East & Africa Overactive Bladder Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 75. Turkey Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. Saudi Arabia Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 77. UAE Overactive Bladder Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 78. Overactive Bladder Drug Value Chain
Figure 79. Overactive Bladder Drug Production Process
Figure 80. Channels of Distribution
Figure 81. Distributors Profiles
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed